2017

Hehlmann, Rüdiger, Lauseker, Michael, Saußele, Susanne, Hochhaus, Andreas, Hasford, Joerg, Pfirrmann, Markus, Kolb, Hans-Jochem, Spiekermann, Karsten, Fabarius, Alice, Müller, M. C., Proetel, Ulrike, Kohlbrenner, K., Voskanyan, A., Rinaldetti, S., Seifarth, W., Spieß, B., Krause, S. W., Neubauer, A., Burchert, A., Hossfeld, Dieter K., Schafhausen, P., Nerl, C., Gratwohl, A., Heim, D., Baerlocher, Gabriela M., Brümmendorf, Tim H., Fuchs, R., Haferlach, C., Jeromin, S., Schlegelberger, Brigitte, Balleisen, L., Goebeler, M. C., Hänel, M., Ho, A., Dengler, J., Falge, C., Kanz, L., Kremers, S., Kneba, M., Stegelmann, F., Köhne, C. A., Lindemann, H. W., Waller, C. F., Pfreundschuh, Michael, Berdel, Wolfgang E., Müller, L., Edinger, M., Mayer, J., Beelen, D. W., Bentz, M., Link, H., Hertenstein, Bernd, Wernli, Martin, Schlegel, F., Schlag, R., Wit, M. de, Trumper, L., Hebart, H., Hahn, M., Thomalla, J., Scheid, C., Verbeek, W., Eckart, M. J., Gassmann, W., Pezzutto, A., Schenk, M., Brossart, P., Geer, T., Bildat, S. and Schäfer, E. (2017): Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. In: Leukemia, Vol. 31, Nr. 11: S. 2398-2406

2016

Gratwohl, A., Pfirrmann, Markus, Zander, A., Kröger, N., Beelen, D., Novotny, J., Nerl, C., Scheid, C., Spiekermann, Karsten, Mayer, J., Sayer, H. G., Falge, C., Bunjes, D., Döhner, H., Ganser, A., Schmidt-Wolf, I., Schwerdtfeger, R., Baurmann, H., Kuse, R., Schmitz, N., Wehmeier, A., Fischer, J. T., Ho, A. D., Wilhelm, M., Goebeler, M. E., Lindemann, H. W., Bormann, M., Hertenstein, B., Schlimok, G., Baerlocher, Gabriela M., Aul, C., Pfreundschuh, M., Fabian, M., Staib, P., Edinger, M., Schatz, M., Fauser, A., Arnold, R., Kindler, T., Wulf, G., Rosselet, A., Hellmann, A., Schäfer, E., Prümmer, O., Schenk, M., Hasford, Joerg, Heimpel, H., Hossfeld, D. K., Kolb, H.-J., Büsche, G., Haferlach, C., Schnittger, S., Müller, M. C., Reiter, A., Berger, Ute, Saußele, Susanne, Hochhaus, A. and Hehlmann, R. (2016): Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment. In: Leukemia, Vol. 30, Nr. 3: S. 562-569

2003

Hehlmann, R., Berger, Ursula, Pfirrmann, Markus, Hochhaus, A., Metzgeroth, G., Maywald, O., Hasford, Joerg, Reiter, A., Hossfeld, D. K., Kolb, H. J., Löffler, H., Pralle, H., Queisser, W., Griesshammer, M., Nerl, C., Kuse, R., Tobler, A., Eimermacher, H., Tichelli, A., Aul, C., Wilhelm, M., Fischer, J. T., Perker, M., Scheid, C., Schenk, M., Weiss, J., Meier, C. R., Kremers, S., Labedzki, L., Schmeiser, T., Lohrmann, H. P., Heimpel, H., Kolb, H.-J. and Lohrmann, H.-P. (2003): Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea. In: Leukemia, Vol. 17, Nr. 8: S. 1529-1537

1994

Gille, Peter, Hollatz, M., Kleessen, H. and Schenk, M. (1994): Axially linear slopes of composition for “delta” crystals. In: Journal of Crystal Growth, Vol. 139, Nr. 1-2: S. 165-171 [PDF, 415kB]

1990

Krause, R., Klimakow, A., Kießling, F. M., Polity, A., Gille, Peter and Schenk, M. (1990): Study of Hg vacancies in (Hg,Cd)Te after THM growth and post-growth annealing by positron annihilation. In: Journal of Crystal Growth, Vol. 101, Nr. 1-4: S. 512-516 [PDF, 337kB]

1988

Gille, Peter, Herrmann, K. H., Puhlmann, N., Schenk, M., Tomm, J. W. and Werner, L. (1988): Eg versus x relation from photoluminescence and electron microprobe investigations in p-type Hg1−xCdxTe (0.35 =< x =< 0.7). In: Journal of Crystal Growth, Vol. 86, Nr. 1-4: S. 593-598 [PDF, 321kB]

1984

Gille, Peter and Schenk, M. (1984): Structural Incorporation and Electrical Efficiency of Tl in PbTe. In: physica status solidi (a), Vol. 84, Nr. 2: K121-K124 [PDF, 151kB]